John Michael Reynolds

Professor of Medicine

Medicine, Pulmonary, Allergy, and Critical Care Medicine

john.m.reynolds@duke.edu

ORCID iD

https://orcid.org/0000-0003-4766-8852

More About This Person

At a Glance

Credentials
1. Education

Academic Experience
1. Current Duke Appointments & Affiliations
2. Previous Duke Appointments & Affiliations

Global Scholarship

Keywords

Research
1. Selected Grants

Scholarly Works

Teaching & Mentoring

Recognition
1. News Items

Professional Activities

Embed Profile Data

Embed Profile Data

Selected Grants

Lung Transplant Clinical Trial Network (LT-CTN)

ResearchSite PI · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2028

ECP Management of BOS

Clinical TrialPrincipal Investigator · Awarded by Washington University in St. Louis · 2018 - 2027

CTOT - CFF - Extension

ResearchSite PI · Awarded by Cystic Fibrosis Foundation · 2021 - 2027

Cystic Fibrosis Lung Transplant Consortium

ResearchCo Investigator · Awarded by Cystic Fibrosis Foundation · 2020 - 2026

BT-L-CsA-302-DLT BOSTON-3

Clinical TrialPrincipal Investigator · Awarded by BREATH Therapeutics · 2020 - 2025

A phase III clinical trial to demonstrate the effectiveness and safety of Liposomal Cyclosporine A (L-CsA) inhalation solution delivered via the PARI Investigational eFlow device plus standard of care v. standard of care of BOS in double lung transpl

Clinical TrialPrincipal Investigator · Awarded by Zambon SpA · 2019 - 2025

A phase III clinical trial to demonstrate the effectiveness and safety of Liposomal Cyclosporine A (L-CsA) inhalation solution delivered via the PARI Investigational eFlow device plus standard of care v. standard of care of BOS in single lung transpl

Clinical TrialPrincipal Investigator · Awarded by Zambon SpA · 2019 - 2025

Interdisciplinary Training Program in Lung Disease

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2009 - 2021

Cystic Fibrosis Lung Transplant Consortium

ResearchCo Investigator · Awarded by Cystic Fibrosis Foundation Therapeutics, Inc. · 2017 - 2019